Peptic ulcer (gastric ulcer and duodenal ulcer) is very common chronic disorder of stomach which is mainly caused by the damage or impairment of stomach lining. Various factors such as pepsin, gastric acid, H. pylori, NSAIDs, prostaglandins, mucous, bicarbonate and blood flow to mucosa play an important role in causing peptic ulcer. In this review article, our main focus is on some important approaches (floating, bioadhesive, high density, swellable and magnetic systems) which are helpful in gastro retention of different dosage forms for treatment of peptic ulcer. Various factors such as composition of meal, nature of meal, gender, age, posture, size, shape, density of the dosage form influence the efficiency of above approaches. Currently, a lot of work is running to improve different types of gastro retentive delivery systems of a wide range of drugs and compensate the effects of above factors. In the future, it is anticipated that they will become of growing significance, finally leading to improved efficiency of various types of pharmacotherapies.
1. Matsuhashi N. [Peptic ulcer (gastro-duodenal ulcer, acute gastric mucosal lesion, NSAIDs- induced ulcer)]. Nihon rinsho Japanese Journal of Clinical Medicine. 2012;70 Suppl 6: 553-6.
2. Lu LS, Lin SC, Kuo CM, Tai WC, Tseng PL, Chang KC, et al. A real world report on intravenous high-dose and non-high-dose proton-pump inhibitors therapy in patients with endoscopically treated high-risk peptic ulcer bleeding. Gastroenterology Research and Practice. 2012;2012: 858612.
3. Singh JA, Lewallen DG. Peptic ulcer disease and heart disease are associated with periprosthetic fractures after total hip replacement. Acta Orthopaedica. 2012;83(4): 353-9.
4. Shiotani A, Kamada T, Haruma K. [NSAID-associated peptic ulcer and H. pylori infection]. Nihon Shokakibyo Gakkai zasshi = The Japanese Journal of Gastro-Enterology. 2012;109(1): 54-9.
5. Haruma K, Kamada T, Shiotani A. [Adverse effects of drugs for peptic ulcer diseases]. Nihon rinsho Japanese Journal of Clinical Medicine. 2012;70 Suppl 6: 266-71.
6. Levin DA, Watermeyer GA, Deetleefs E, Metz DC, Thomson SR. The efficacy of endoscopic therapy in bleeding peptic ulcer patients. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2012;102(5): 290-3.
7. Adhikary A, Vavia PR. Bioadhesive ranitidine hydrochloride for gastroretention with controlled microenvironmental pH. Drug Development and Industrial Pharmacy. 2008; 34(8): 860-9.
8. El Gamal SS, Naggar VF, Allam AN. Optimization of acyclovir oral tablets based on gastroretention technology: factorial design analysis and physicochemical characterization studies. Drug Development and Industrial Pharmacy. 2011;37(7): 855-67.
9. Patil GB, Singh SS, Ramani KP, Chatap VK, Deshmukh PK. Design and development of novel dual-compartment capsule for improved gastroretention. ISRN Pharmaceutics. 2013; 2013: 752471.
10. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Delivery. 2011;18(2): 97-110.
11. Kiss D, Zelko R. [Gastroretentive dosage forms]. Acta pharmaceutica Hungarica. 2005;75(3): 169-76.
12. Klausner EA, Lavy E, Barta M, Cserepes E, Friedman M, Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharmaceutical Research. 2003;20(9): 1466-73.
13. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. Journal of controlled release : official journal of the Controlled Release Society. 2003; 90(2): 143-62.
14. Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharmaceutical Research. 2002;19(10): 1516-23.
15. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. Journal of controlled release : official journal of the Controlled Release Society. 2006;111(1-2): 1-18.
16. Groning R, Cloer C, Georgarakis M, Muller RS. Compressed collagen sponges as gastroretentive dosage forms: in vitro and in vivo studies. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. 2007; 30(1): 1-6.
17. Gurnany E, Manwani R, Singhai P, Jain R, Jain A. Gastro-retentive Floating Multiparticulate Drug Delivery System: A Review. Current Drug Delivery. 2012.
18. Moes AJ. Gastroretentive dosage forms. Critical reviews in therapeutic drug carrier systems. 1993;10(2): 143-95.
19. Nama M, Gonugunta CS, Reddy Veerareddy P. Formulation and evaluation of gastroretentive dosage forms of Clarithromycin. AAPS PharmSciTech. 2008;9(1): 231-7.
20. Shirsand SB, Suresh S, Jodhana LS, Swamy PV. Formulation design and optimization of fast disintegrating Lorazepam tablets by effervescent method. Indian Journal of Pharmaceutical Sciences. 2010;72(4): 431-6.
21. Getyala A, Gangadharappa HV, Prasad MS, Reddy MP, Kumar TM. Formulation and evaluation of non-effervescent floating tablets of losartan potassium. Current Drug Delivery. 2013;10(5): 620-9.
22. Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. Journal of Pharmacy and Bioallied Sciences. 2011;3(1): 89-100.
23. Boddupalli BM, Mohammed ZN, Nath RA, Banji D. Mucoadhesive drug delivery system: An overview. Journal of Advanced Pharmaceutical Technology and Research. 2010;1(4):381-7.
24. Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Critical Reviews in Therapeutic Drug Carrier Systems. 2013;30(5):369-409.
25. Arza RA, Gonugunta CS, Veerareddy PR. Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride tablets. AAPS PharmSciTech. 2009;10(1):220-6.
26. Conway BR. Drug delivery strategies for the treatment of Helicobacter pylori infections. Current Pharmaceutical Design. 2005;11(6):775-90.
27. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Critical Reviews in Therapeutic Drug carrier Systems. 2012;29(1):1-63.
28. Murphy CS, Pillay V, Choonara YE, du Toit LC. Gastroretentive drug delivery systems: current developments in novel system design and evaluation. Current Drug Delivery. 2009;6(5):451-60.
29. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Critical Reviews in Therapeutic Drug Carrier Systems. 1998;15(3):243-84.
30. Parnami N, Garg T, Rath G, Goyal AK. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol. 2013.
31. Dehvari K, Lin KS. Synthesis, characterization and potential applications of multifunctional PEO-PPOPEO- magnetic drug delivery system. Current Medicinal Chemistry. 2012;19(30):5199-204.